Preclinical study of binary catalytic systems as radio/chemomodifiers

The investigators conducted a preclinical study of the antitumor efficacy of the combined use of an Oxycobalamin-lio (Ox-lio) + Efiter acid-based binary catalytic system (BCS) with radiation and chemoradiation therapy. The incorporation of the BCS Ox-lio + ascorbic acid (Aa), which was used as independent antitumor agents, into a chemoradiation therapy regimen, was shown to lead to biologically important tumor growth suppression throughout the observation and to promote the potentiated therapeutic effect of radiation/chemotherapy. The therapeutic effectiveness of the Ox-lio + Aa BCS used as a modifier is higher than the Efiter + Ac BCS, which seems to be due to its detoxifying activity. The findings suggest the expediency of a clinical trial of the Ox-lio + Ac BCS as a modifier of medical treatments in patients with malignancies.

binary catalytic system, Oxycobalamin-lio, Efiter, chemomodifier, radiomodifier